ABSTRACT
INTRODUCTION
Infection with Epstein-Barr virus (EBV) accompanies most humans throughout their life. In healthy carriers, the virus is under continuous control by EBV-specific T cells 1 There is up to now no standardized treatment for PTLD 2, 5 . Reduction in immunosuppression is generally used as a first step but carries the inherent risk of triggering or aggravating graftversus-host disease. A considerable proportion (50% or more) of PTLD cases responds to the anti-CD20 antibody rituximab 5, 6 , which is therefore widely used for treatment or prophylaxis, but may completely delete B cells for several months to years. Rituximab treatment may fail due to downregulation of the CD20 antigen on malignant B cells or due to absence of effector cells of antibody-mediated cellular cytotoxicity. Infusion of donor lymphocytes is an efficient treatment for PTLD but carries the risk of severe graft-versus-host disease 7 . In contrast, adoptive transfer of pre-selected EBV-specific T cells, pioneered by Rooney and colleagues, was clinically efficient and safe in prophylaxis and therapy of PTLD after HSCT 8-10 and led to long-lasting engraftment of the transferred T cells 8, 11 . In this approach, donor-derived B cell lines transformed with EBV in vitro (lymphoblastoid cell lines) were used to select and expand EBV-specific T cells from the donor's repertoire. However, generation of a donorderived LCL and the repeated restimulation of donor T cells require two to three months of processing time 10, 12 . This precludes the preparation and use of such T cells after PTLD has become manifest, and such a process requires substantial workforce and laboratory facilities.
Therefore, more rapid methods to prepare EBV-specific T cells are required to make EBVspecific T cell therapy more widely applicable.
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Here, we present a novel method for the rapid isolation of clinical-grade EBV-specific T cells and describe its use in PTLD therapy. EBV-specific T cells were isolated from donor blood cells in less than 36 hours by stimulation with a pool of 23 EBV peptide epitopes from 11 EBV antigens, followed by isolation of responding cells by antibody-mediated surface interferon-γ capture and immunomagnetic separation 13, 14 . Rapidly isolated EBV-specific T cells were used for adjuvant treatment of six patients with manifest PTLD. We describe clinical responses and immune reconstitution in these patients after EBV-specific T cell transfer.
PATIENTS AND METHODS

Isolation of EBV-specific T cells
EBV-specific T cells for adoptive transfer to patients after allogeneic HSCT were prepared from lymphocyte-rich leukapheresis products from the transplant donor. In each case, the donor was EBV-positive (positive for IgG to EBNA1 and VCA). To stimulate EBV-specific T cells to secrete IFN-γ, leukapheresis products were resuspended at 10 7 cells/ml in VLE RPMI-1640 medium (very low endotoxin, Biochrom, Berlin, Germany) supplemented with 10% pooled human male AB serum (Institute for Tranfusion Medicine, Suhl, Germany). EBV peptide mix (1μg/ml of each peptide) was added, and the cells were incubated for 12 hours at 37°C in a culture bag (LifeCell, Baxter, Deerfield, IL). A total of 1.5 -2.5 ×10 9 cells were used for stimulation. The EBV peptide mix consisted of 23 peptides of 8 to 15 amino acids in length (>95% purity, purchased from JPT, Berlin, Germany), listed in Table 1 . Peptides were individually dissolved at 10 μg/ml in DMSO, pooled and stored at -20°C.
After the 12-hour stimulation period, IFN-γ-secreting cells were isolated using the IFN-γ
Cytokine Capture System and a CliniMACS separation device, according to the 
Patients
Between January and December 2007, six patients after allogeneic HSCT who developed biopsy-proven EBV-positive PTLD that showed signs of progression during short-term (3-14 days) therapy (reduction in immunosuppression, rituximab and cidofovir) received a single transfusion of EBV-specific T cells directly prepared from peripheral blood of their donor. All patients gave informed consent. Patient data are provided in Table 4 . T cells were intravenously infused via a central line over a period of 10 minutes in 35 to 37 ml of PBS/EDTA buffer with 0.5% human AB serum. The protocol was approved by the IRB of Ludwig-Maximilians-Universität, Munich.
Quantification of EBV DNA by PCR in peripheral blood cells or throat lavage was performed at least weekly using primers detecting a sequence in EBV's DNA polymerase gene, BALF5 15 . Levels of EBV DNA ( Fig. 2-4 ) refer to 20,000 PBMCs, or 1 ml of throat lavage or endotracheal suctioning.
Analysis of immune reconstitution
For analysis of T cell responses in patients after T cell transfer, 30-ml samples of heparinized blood were obtained by venipuncture. Peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation on Ficoll (Biochrom). Table 1 . PBMCs were stained with the respective pentamer reagent at 20°C for 10 minutes, washed, and counterstained with a mixture of fluorotag, anti-CCR7-FITC (R&D Systems), anti-CD45RA-PE-Cy5, and anti-CD8-APC (both BD Pharmingen). In negative control stainings, buffer without HLA/peptide pentamer was used in the first step.
A parallel staining was performed using anti-CD4-FITC, anti-CD8-PE, anti-CD3-PE-Cy5 (all BD Pharmingen), and anti-CD56-APC (BioLegend). For analysis of their TCR Vβ subclass composition, cells were stained with each of the eight antibody sets contained in the IOTest BetaMark kit (Beckman-Coulter), which contains 24 antibodies against specific Vβ regions, For personal use only. on October 22, 2017. by guest www.bloodjournal.org From labeled with fluorescein, PE or both, and counterstained with anti-CD4-PECy5 (ImmunoTools) and CD8-APC (BD Pharmingen).
IFN-γ ELISPOT analysis was performed in 96-well mixed cellulose ester plates (Millipore) with antibody sets from Mabtech (Nacka, Sweden). PBMCs were stimulated with relevant peptides or peptide mixes (1 μg/ml for each peptide), 12-O-tetradecanoylphorbol-13-acetate (100 ng/ml, Sigma) and ionomycin (1μM/ml, Calbiochem) for a positive control, or medium for a negative control.
T cell clones were established from peripheral blood cells by distributing PBMCs at 0.7 or 3 cells per well to 96-well round-bottom plates in the presence of mixed irradiated (50 Gy) pooled PBMCs from three anonymous donors (together 1.5×10 6 /ml), irradiated lymphoblastoid cell line from an irrelevant donor (10 5 /ml), and interleukin-2 (1000 IU/ml, Proleukin, Chiron). After 2.5 to 3 weeks, outgrowing clones were screened for antigenspecific reactivity in an ELISA (Mabtech) by stimulation with relevant EBV peptides. For further expansion, clones were restimulated every two weeks using the same set of stimuli (allogeneic PBMC, LCL, interleukin-2).
RESULTS
Rapid isolation of EBV-specific T cells
For therapy of PTLD, we developed a rapid method to isolate EBV-specific T cells from donor peripheral blood leukaphereses by stimulation with a pool of EBV-derived peptides and subsequent immunomagnetic isolation of IFN-γ-secreting cells (Figure 1) 
Transfusion of EBV-specific T cells to patients with PTLD
Six patients with PTLD after allogeneic HSCT (Table 4) Table 2) .
Remission of lymphomas and expansion of EBV-specific T cells after T cell transfer
After T cell transfer, we observed a rapid and complete remission of PTLD in patients 1, 2, and 3. Patients 1 and 2 have remained alive and healthy ever since (for more than two years).
In patient 1, lymphadenopathy and clinical symptoms had completely resolved by day 16 after T cell transfer, and a biopsy was negative for malignant cells and for EBV DNA. EBV DNA in PBMC and throat lavage had become undetectable earlier ( Figure 2A ). Before T cell transfer, this patient had low CD4+ T cell counts, but CD8+ T cell counts in the upper normal range. After T cell transfer, total CD8+ T cells rapidly expanded threefold and remained Figure 3A ). EBV-specific T cell reconstitution ( Figure 3C ) was dominated by T cells specific for lytic-cycle epitopes YVL and GLC. YVL-specific T cells rapidly expanded after transfer and peaked at 20% of lymphocytes. T cells specific for each of the two epitopes were maintained at high numbers for several months, followed by a contraction, and were maintained at lower numbers later; T cells specific for two latent epitopes (in patient 2, CLG and RRIY) were detected, but at lower numbers than lytic antigen-specific T cells. Overall, patterns of T cell reconstitution in patient 1 and patient 2 were very similar.
Rapid remission of PTLD after T cell transfer was also observed in patient 3, and was associated with elimination of detectable EBV DNA in blood cells and throat ( Figure 4A ). This patient had very low levels of T cells before transfer ( Figure 4B ). No HLA/peptide pentamers were available for the donor's HLA type. In ELISPOT analyses, we observed a rapid increase of T cells recognizing the B44-restricted epitope VEI from the latent antigen EBNA3B, and against the DR15-restricted epitope TDAW from the structural protein BNRF1
( Figure 4C ). The dominant VEI specificity reached a peak on day 17 after transfer, reminiscent of the kinetics of T cell expansion in patients 1 and 2. After T cell transfer, patient 3 remained free of EBV-associated disease, and EBV DNA remained undetectable. However, two months after T cell transfer the patient developed idiopathic pneumonitis. A lung biopsy showed infiltration of monocytic cells, but not T cells. Patient 3 ultimately died from lung failure 96 days after T cell transfer.
Taken together, in all of three patients with early-stage PTLD we witnessed a complete remission of PTLD after transfer of small numbers of EBV-specific T cells. No side effects
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From associated with T cell infusion and no graft-versus-host disease was observed. In each of these patients, PTLD remission was associated with a strong expansion of EBV-specific T cells in the periphery. Antigen-specific T cells were found for a majority of EBV epitopes in the peptide pool that were restricted through the donors' HLA allotypes (Table 5) : T cells from patient 1 recognized 4 of 7 matched epitopes; patient 2 recognized 5 of 6 epitopes; patient 3 recognized 2 of 3 epitopes. All were CD8+ T cell epitopes, with one exception: in patient 3, some T cells recognized TDAW, a recently identified EBV epitope 16 from a structural protein, BNRF1, which is recognized by CD4+ T cells in most healthy EBV carriers and often dominates their CD4+ T cell response 18 .
No remission of PTLD in patients with late-stage disease
In contrast to these patients, patients 4 to 6 had late-stage PTLD with multi-organ dysfunction at the time of T cell transfer (Table 4) . After transfer, all three patients continued to suffer from progressive disease ( Table 4 , Figure 5 ). Immunoreconstitution could not be analyzed in Figure 5I ). HLA/peptide pentamer staining could not be performed due to low available cell numbers. In ELISPOT assays, low reactivity to polyclonal stimulation and no reactivity to EBV epitopes was seen ( Figure 5J ). Patient 6 died from multi-organ failure on day 7 after T cell transfer. Taken together, in all three patients with advanced PTLD there was progression of disease after T cell transfer, and EBV-specific T cell responses were weak or absent (Table 5) .
T cell repertoire after T cell transfer and remission of PTLD
In patients 1 and 2, who have remained alive and well for more than two years after T cell transfer, we investigated the diversity of the patients' T cell repertoire by T cell receptor β chain variable domain (TCR Vβ) staining and flow cytometry. For several months, both
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From patients maintained a highly restricted TCR repertoire with only about four dominant TCR Vβ classes, indicating the presence of a similarly limited number of expanded clonotypes ( Figure   6 ). In contrast, when such analyses were performed more than a year after T cell transfer, a diversified repertoire of TCR Vβ classes was found in both donors. Total T cell diversification ( Figure 6 ) was broadly coincident with contraction of EBV-specific T cell reactivities and inversion of the CD8+ to CD4+ T cell ratio ( Figure 2C and 3C ).
Memory phenotypes of EBV-specific T cells after transfer
Expression of lymphocyte homing markers, chemokine receptors and isoforms of CD45 is linked to the functional role of T cell subsets at different stages of differentiation [19] [20] [21] . We analyzed differentiation stages of EBV-specific T cells in patient 1 and 2. Figure 7 shows analyses of a representative T cell specificity for a lytic-cycle antigen and a latency antigen in each patient. We analyzed EBV-specific T cells during the early expansion phase (day 3 or 7 after transfer), during maintenance at high levels (day 38 or 40), and after contraction of the EBV-specific T cell response (day 657 or 643). Both latent and lytic antigen-specific T cells had an effector memory phenotype (CCR7-CD45RA-) early after transfer in both patients, consistent with the T cells' presumed functional role at this time. In both patients, T cells specific for latent antigens partially acquired CCR7 expression after T cell contraction, as shown for CLG-specific T cells in patient 1 and RRIY-specific T cells in patient 2 (Figure 7 A, B). In patient 1, T cells specific for the lytic antigen-derived epitopes GLG ( Figure 7A) and YVL (not shown) showed a similar pattern of partial acquisition of CCR7, indicating central memory differentiation. In patient 2, however, T cells specific for lytic antigen epitopes (YVL, Figure 7B ; GLC, not shown) reassumed expression of CD45RA over time, and remained CCR7-negative.
Thus, contrasting differentiation patterns of EBV-specific T cells may be observed in allogeneic HSCT patients after T cell transfer. Dominant lytic antigen-specific CD8+ T cells may either assume a CCR7+CD45RA-central memory or a CCR7-CD45RA+ "terminal" effector phenotype, and both phenotypes are compatible with long-term T cell maintenance and control of viral reactivation after PTLD remission. This is consistent with the notion that CCR7-CD45RA+ T cells are functional memory cells with reduced proliferation but full direct antiviral effector function 21, 22 . Of note, EBV DNA consistently remained undetectable in peripheral blood cells and throat lavages of patient 1 after PTLD remission, while patient 2
remained negative for EBV DNA in the blood, but continued to replicate EBV in the throat at low levels after T cell transfer for two years ( Figure 3A and not shown). Thus, continuous challenge with lytic antigen at low levels may induce a CCR7-CD45RA+ phenotype in responsive T cells 22 .
For
DISCUSSION
We describe the clinical application of a novel rapid method to prepare EBV-specific T cells for adoptive therapy of EBV-associated PTLD after allogeneic HSCT. Six patients with manifest PTLD at different stages of progression obtained a transfusion of EBV-specific T cells that had been isolated from donor blood cells in a 36-hour procedure. In three patients with very advanced PTLD, the disease progressed in spite of T cell transfer. However, in three patients with early disease we observed complete remission of PTLD and rapid reconstitution of EBV-specific T cells after T cell transfer. Our results illustrate the importance of an early, if possible prophylactic or pre-emptive management of PTLD 5, 23 , and suggest that the transfer of small numbers of EBV-specific T cells might be beneficial in such a situation. This seems encouraging and demands verification in a larger study.
However, some notes of caution are warranted. First, in addition to EBV-specific T cells, all patients received additional treatments (reduction in immunosuppression, anti-CD20, and cidofovir), and these might have contributed to remission of disease after T cell transfer, although PTLD appeared to progress before T cell transfer. Rituximab therapy of overt PTLD after HSCT was successful in 63% of cases 23 ; in patients who respond to rituximab, signs of clinical response are generally seen within one week of treatment 24 . Because we did not observe such signs in any of our patients before T-cell transfer, it might be hypothesized that some or all of them were non-responders to rituximab. This seems to be corroborated by our observation that EBV DNA levels did not decrease before T cell transfer in 5 of 6 patients (patient 1 being the exception); while a rapid decrease of EBV DNA is typical in rituximab responders, it is sometimes observed in some non-responders as well 24, 25 . Second, donorderived EBV-specific T cells might already have been present in the patients before T cell transfer and could, by coincidence, have expanded after T cell therapy. Derived from the same donor's EBV-specific T cell repertoire, such pre-existing T cells could not be clearly distinguished from T cells transferred later as a therapeutical procedure. Gene marking of the transferred T cells 9 could resolve this question, but will not be available in the foreseeable future because it would involve a complex technical procedure, in the absence of a direct beneficial effect for the patient. Therefore, larger studies will be needed to demonstrate a clear association between PTLD protection and EBV-specific T cell transfer.
org From
Our observations are consistent with previous studies on EBV-specific T cell therapy of PTLD after allo-HSCT that demonstrated therapeutic and prophylactic efficacy [8] [9] [10] [25] [26] [27] . In these studies, a donor-derived EBV-infected B cell line was generated and used to repeatedly restimulate donor T cells, a process which requires two to three months of time. Therefore, such T cells were in most cases used for prophylaxis rather than therapy, or had to be prepared in advance for patients at high risk of PTLD from the HSCT donor 11 . In most of these studies, isolated T cells had to be expanded in vitro for several days to produce cell numbers sufficient for analysis. However, in a clinical study of adenovirus-specific T cells 32 , small numbers of isolated T cells were directly transferred to the patients and in some cases expanded in vivo.
The preparation of EBV-specific T cells can be accelerated by using formalin-fixed LCLs as stimulators in combination with IFN-γ secretion-based isolation 33 . Adenoviral vectors expressing EBV LMP2 and CMV pp65 and IFN-γ-based isolation were used to prepare T cells specific for all three viruses 34 . Selected epitopes from EBV and CMV were used in an alternative T cell isolation method 35 based on induction of CD137 (4-1BB). However, a method to prepare multiepitope EBV-specific T cells in only two days has not been available so far. We anticipate that the ongoing development of rapid isolation methods for virusspecific T cells will help make virus-specific T cell therapy more widely available to the patients in need.
An important goal of T cell therapy is long-term protection by stable establishment of a functional T cell memory. In two of our patients (patient 1 and 2), who have remained alive and healthy for more than two years by now, long-term follow-up was possible after T cell transfer. EBV-specific T cell reconstitution was strikingly similar between these two patients,
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From who (and whose donors) happened to be HLA-A2-positive. In both patients, we observed a strong expansion of EBV-specific T cells after adoptive transfer, maintenance at high numbers for about six months, subsequent contraction, and stabilization at lower numbers reminiscent of healthy carriers. In both patients, the expansion of EBV-specific T cells was dominated by T cells recognizing the same two epitopes (YVL and GLC) from immediateearly and early lytic cycle antigens (Figures 2 and 3 ). Peak numbers of T cells specific for these two epitopes were high (21% and 20% of PBL for the YVL epitope in patient 1 and 2, respectively, corresponding to 490 and 760 specific cells/μl) and much above the frequencies of these T cell specificities in healthy EBV carriers 20 . However, similarly elevated numbers of T cell specific for dominant EBV epitopes may spontaneously develop in some patients after 2008;31 (7):665-674.
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